Phase 1B Trial: Evaluation of the Safety of Adding Brentuximab Vedotin to Low-Dose Total Skin Electron Beam (TSEB) for Treatment of Patients With Mycosis Fungoides and Sézary Syndrome
Latest Information Update: 18 Jul 2023
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Mycosis fungoides; Sezary syndrome
- Focus Adverse reactions; Therapeutic Use
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 29 Aug 2019 Status changed from active, no longer recruiting to completed.
- 22 Feb 2019 Planned End Date changed from 31 Oct 2024 to 31 Jan 2021.